{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:33:22Z","timestamp":1786120402913,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4,15]]},"DOI":"10.1097\/qai.0b013e31824bb720","type":"journal-article","created":{"date-parts":[[2012,1,31]],"date-time":"2012-01-31T05:49:01Z","timestamp":1327988941000},"page":"489-493","source":"Crossref","is-referenced-by-count":34,"title":["Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir\/Ritonavir in Treatment-Experienced Patients"],"prefix":"10.1097","volume":"59","author":[{"given":"Catherine","family":"Fagard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Rami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Jacomet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Yeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Vittecoq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Ch\u00eane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-9-20210131","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/630210","article-title":". High rate of virologic suppression with raltegravir plus etravirine and darunavirritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.","volume":"49","author":"Yazdanpanah","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R3-9-20210131","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0b013e318157131c","article-title":". Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.","volume":"46","author":"Markowitz","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R4-9-20210131","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":". Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"R5-9-20210131","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1097\/QAD.0b013e32833ed2a7","article-title":". Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavirritonavir regimen.","volume":"24","author":"Charpentier","year":"2010","journal-title":"AIDS"},{"key":"R6-9-20210131","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0b013e3181c990bf","article-title":". Once-daily atazanavirritonavir compared with twice-daily lopinavirritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.","volume":"53","author":"Molina","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R7-9-20210131","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/QAI.0b013e3181b064b0","article-title":". Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.","volume":"52","author":"Markowitz","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R8-9-20210131","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e3181da1287","article-title":". Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.","volume":"55","author":"Lennox","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R9-9-20210131","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/ije\/30.4.864","article-title":". Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts.","volume":"30","author":"Yazdanpanah","year":"2001","journal-title":"Int J Epidemiol"},{"key":"R10-9-20210131","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1086\/605594","article-title":". Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort.","volume":"49","author":"Bruyand","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R11-9-20210131","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnci\/djr076","article-title":". Cancer burden in the HIV-infected population in the United States.","volume":"103","author":"Shiels","year":"2011","journal-title":"J Natl Cancer Inst"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAI.0b013e31824bb720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:33:08Z","timestamp":1786048388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-201204150-00009"}},"subtitle":["Week 96 Results From the ANRS 139 TRIO Trial"],"short-title":[],"issued":{"date-parts":[[2012,4,15]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31824bb720","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4,15]]}}}